Global Prostate Cancer Diagnostics Market 2018-2025: Projected to Reach $5.5 Billion by 2025 - Analysis by Type & Region - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Prostate Cancer Diagnostics Market Analysis Report By Type (Preliminary Tests, Confirmatory Tests), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025” report has been added to ResearchAndMarkets.com’s offering.The global prostate cancer diagnostics market size is expected to reach USD 5.5 billion by 2025. The market is estimated to expand at a CAGR of 12.3% during the forecast years.Demand for prostate cancer diagnostics is increasing owing to rising prevalence of the disease along with constant technological advancements and awareness regarding the same.
Every year, more than 230,000 men are diagnosed with prostate cancer. In addition, as per a study conducted by the American Cancer Society, prostate cancer is the third leading cause of cancer-related deaths in U.S. Constant development of new technologies for the disease diagnosis and treatment would drive the market over the coming years.
Magnetic Resonance Imaging (MRI) technology and Fusion biopsy are the new technologies used for the disease diagnosis. Fusion biopsy is a technique, which uses the combination of MRI and ultrasound.
Further key findings from the study suggest:Increasing prevalence of prostate cancer is primarily boosting the market growth across the globeGrowing awareness regarding the disease and available treatments along with supportive government initiatives would also drive the marketThe preliminary tests segment captured the largest market share of prostate cancer diagnostics in 2016Confirmatory tests segment is said to expand at the fastest CAGR due to low risk of infection, convenience, and non-invasive nature of these testsNorth America is the dominant regional market followed by Europe due to sophisticated healthcare infrastructure and availability of technologically advanced productsCompanies FeaturedMDxHealth3D SignaturesGenomic HealthAbbottOPKO Health, Inc.Siemens Healthcare GmbHDiaSorin S.p.A.bioMrieux SAF. Hoffman La Roche Ltd.Beckman Coulter, Inc.Myriad Genetic, Inc.
Key Topics Covered
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Prostate Cancer Diagnostics Market Variables, Trends & Scope
Chapter 4 Prostate Cancer Diagnostics Market: Type Estimates & Trend Analysis
Chapter 5 Prostate Cancer Diagnostics Market: Regional Estimates & Trend Analysis, by Type
Chapter 6 Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/research/5srv4v/global_prostate?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005533/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Diagnostics,Prostate Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/25/2018 06:09 AM/DISC: 09/25/2018 06:09 AM